KEGG   DRUG: D05697Help
Entry
D05697                      Drug                                   

Name
Ranibizumab (genetical recombination) (JAN);
Ranibizumab (USAN/INN);
Lucentis (TN)
Product
Formula
C2158H3282N562O681S12
Exact mass
48349.6111
Mol weight
48379.2865
Activity
Treatment of age-related macular degeneration [DS:H00821]
Remark
Therapeutic category: 
ATC code: 
Comment
monoclonal antibody (humanized IgG1 Fab)
Target
VEGFA [HSA:7422] [KO:K05448]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04370  VEGF signaling pathway  
 
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  13  Agents affecting sensory organs
   131  Ophthalmic agents
    1319  Others
     D05697  Ranibizumab (genetical recombination) (JAN); Ranibizumab (USAN/INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 S SENSORY ORGANS
  S01 OPHTHALMOLOGICALS
   S01L OCULAR VASCULAR DISORDER AGENTS
    S01LA Antineovascularisation agents
     S01LA04 Ranibizumab
      D05697  Ranibizumab (genetical recombination) (JAN); Ranibizumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokines
  PDGF family
   VEGFA [HSA:7422] [KO:K05448]
    Ranibizumab [ATC:S01LA04]
     D05697  Ranibizumab (genetical recombination) (JAN); Ranibizumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
347396-82-1
PubChem: 
DrugBank: 
NIKKAJI: 

» Japanese version   » Back

DBGET integrated database retrieval system